Summary

The updated UK Clinical Trials Regulation s mandate that sponsors retain the Trial Master File and all essential records for a minimum of 25 years for trials submitted on or after 28 April 2026. This obligation is embedded in law, aligned with ICH E6(R3), and fully enforceable by the MHRA. Failure to comply is not a documentation gap it is regulatory non-compliance.

Crucially, the requirement is not simply to store records for 25 years. Sponsors must be able to demonstrate, at any point during that period, that records remain complete, authentic, legible, secure, and readily retrievable. This includes documents, structured data, metadata, and audit trails. Records that exist but cannot be accessed, interpreted, or defended during inspection put trial sponsors at risk of major or critical inspection findings.

The shift from five years to twenty-five years fundamentally changes the risk profile of clinical trial recordkeeping. Technology obsolescence, vendor dependency, loss of metadata, and data integrity failures now represent material compliance risks, not operational inconveniences. Short-term archiving approaches, system-dependent storage, and “park and forget” strategies are no longer defensible.

Sponsors must therefore treat retention as long-term digital preservation, supported by appropriate governance, contracts, technology, and funding models. Organisations that act early will reduce inspection risk and protect the long-term value of their clinical data. Those that delay will face growing exposure as inspections begin to test not just whether records exist, but whether they can still stand up as legal evidence decades after trial close.